| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.08 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.052 | 0.08 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.09 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.086 | 0.09 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.063 | 0.09 |